Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Prostate Cancer Clinical Oncology

  • Dan Theodorescu
  • Behfar Ehdaie
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_4781-3


Prostate cancer is a malignant neoplasm that arises in the male prostate gland. Most prostate cancers are adenocarcinoma(95 %). About 4 % have transitional cell morphology and are thought to arise from the lining of the prostatic urethra. Few have neuroendocrine morphology and are believed to arise from the neuroendocrine stem cells normally present in the prostate or from aberrant differentiation programs during cell transformation. Of the adenocarcinomas, 70 % arise in the peripheral zone, 15–20 % in the central zone, and 10–15 % in the transition zone. These zones can sometimes be identified by transrectal ultrasound (TRUS). Most adenocarcinomas are multifocal with synchronous involvement of multiple zones of the prostate, and this may be due to clonal tumors that have spread intraprostatically or/and multiple tumor-initiation sites intraprostatically. In addition, multifocality may indicate a more aggressive tumor biology. The most commonly used system of classifying...


Prostate Cancer Radical Prostatectomy Gleason Score Digital Rectal Examination Watchful Waiting 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Bill-Axelson A, Holmberg L, Filen F et al (2008) Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. Cancer 100(16):1144–1154Google Scholar
  2. Ehdaie B, Atoria CL, Gupta A, Feifer A, Lowrance WT, Morris MJ, Scardino PT, Eastham JA, Elkin EB (2012) Cancer 118(13):3397–406Google Scholar
  3. Fletcher SG, Mills SE, Smolkin ME et al (2006) Case-matched comparison of contemporary radiation therapy to surgery in patients with locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 66:1092–1099CrossRefPubMedGoogle Scholar
  4. Gleason DF (1992) Histologic grading of prostate cancer: a perspective. Hum Pathol 23:273–279CrossRefPubMedGoogle Scholar
  5. Petrylak DP, Tangen CM, Hussain MHA et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520CrossRefPubMedGoogle Scholar
  6. Vickers AJ, Till C, Tangen CM et al (2011) An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst 102(6):462–469CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of Surgery, Urology, School of MedicineUniversity of Colorado Cancer CenterAuroraUSA
  2. 2.Department of Surgery, Urology ServiceMemorial Sloan-Kettering Cancer CenterNew YorkUSA